February 22, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets WASHINGTON, Feb. 22, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions... Read more

February 5, 2024 Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships PAI Top-10 Product Launch

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

January 31, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue... Read more

January 30, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher Reports Fourth Quarter and Full Year 2023 Results

WASHINGTON, Jan. 30, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2023.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion, or $1.50 per diluted common share and non-GAAP adjusted diluted... Read more

January 9, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model... Read more

December 11, 2023 PAI Top-10 Product Launch

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 – Roche (SIX: RO, ROG;... Read more

December 9, 2023 PAI Top-10 Product Launch

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1 At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of... Read more

December 8, 2023 PAI Top-10

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2 Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2 These data will be presented as an oral presentation at the 2023 San Antonio... Read more

December 1, 2023 Lab Top-10 PAI Top-10

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on December 14, 2023 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously... Read more